Proteome Sciences Plc ("Proteome Sciences" or "the Company")
DIRECTOR'S DEALING
Proteome Sciences announces that it has received notification today from James
Malthouse, an Executive Director of the Company, that 50,000 ordinary shares
that were held in his late wife's name have been transferred for a nil
consideration to his adult daughter. As a consequence of this, the shares no
longer form part of his beneficial holdings as defined by the AIM rules.
James Malthouse now has an interest in 250,000 Ordinary Shares of the issued
ordinary share capital of the Company.
Enquiries
Proteome Sciences plc
Christopher Pearce, Chief Executive Officer
Email: christopher.pearce@proteomics.com
James Malthouse, Finance Director
Email: james.malthouse@proteomics.com
Tel: +44 (0)1932 865065
Public Relations for Proteome Sciences
IKON Associates
Adrian Shaw
Tel: +44 (0)1483 535102
Mobile: +44 (0)797 9900733
Email: adrian@ikonassociates.com
Coast Communications
Matt Baldwin
Tel: +44 (0) 1233 503200
Mobile: +44 (0) 7930 439739
Email: matt@coastcommunications.com
Director's Dealing
Earlier from Proteome Sciences
- Further Loan Agreement
- Grant of European Patent
- Notice of Allowance of TMT1 Patent in Canada
- Director's Dealings
- Service Agreement with Onconome Inc.
Later from Proteome Sciences
- Statement re US Patent Allowed
- AIM Rule 26 & Adviser Name
- Press Release re Intronn Inc.
- Statement regarding mailing of interim report
- Statement re Issuance of US Patent
Follow Proteome Sciences into a list and get an email when it puts out news.
Follow Proteome Sciences